CA2369951A1 - Solid pharmaceutical formulations of acid-sensitive proton-pump blockers - Google Patents

Solid pharmaceutical formulations of acid-sensitive proton-pump blockers Download PDF

Info

Publication number
CA2369951A1
CA2369951A1 CA002369951A CA2369951A CA2369951A1 CA 2369951 A1 CA2369951 A1 CA 2369951A1 CA 002369951 A CA002369951 A CA 002369951A CA 2369951 A CA2369951 A CA 2369951A CA 2369951 A1 CA2369951 A1 CA 2369951A1
Authority
CA
Canada
Prior art keywords
omeprazole
acid
preparation
active substance
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002369951A
Other languages
English (en)
French (fr)
Inventor
Robert Heger
Wolfgang Schrof
Jens Rieger
Rudiger Voelkel
Jorg Breitenbach
Jurgen Zeidler
Bernd Liepold
Gunther Berndl
Rudolf Binder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2369951A1 publication Critical patent/CA2369951A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002369951A 1999-04-23 2000-04-11 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers Abandoned CA2369951A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19918434.8 1999-04-23
DE19918434A DE19918434A1 (de) 1999-04-23 1999-04-23 Feste Pharmazeutische Formulierungen von säurelabilen Protonenpumpenblockern
PCT/EP2000/003232 WO2000064414A2 (de) 1999-04-23 2000-04-11 Feste pharmazeutische formulierungen von säurelabilen protonenpumpenblockern

Publications (1)

Publication Number Publication Date
CA2369951A1 true CA2369951A1 (en) 2000-11-02

Family

ID=7905597

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369951A Abandoned CA2369951A1 (en) 1999-04-23 2000-04-11 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers

Country Status (6)

Country Link
EP (1) EP1173152A2 (de)
JP (1) JP2002542275A (de)
BR (1) BR0012735A (de)
CA (1) CA2369951A1 (de)
DE (1) DE19918434A1 (de)
WO (1) WO2000064414A2 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US20150133504A1 (en) * 2012-05-02 2015-05-14 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
US10695332B2 (en) 2012-05-02 2020-06-30 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction
US10702509B2 (en) 2011-01-31 2020-07-07 Newmarket Pharmaceuticals Llc Animal treatments

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
ES2333645T3 (es) 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
KR20040011549A (ko) 2001-06-22 2004-02-05 화이자 프로덕츠 인크. 저용해도 및(또는) 산-민감성 약물 및 중화된 산성중합체를 포함하는 제약 조성물
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
WO2006069159A2 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
CN101312953B (zh) 2005-11-17 2013-09-04 强恩有限公司 含硫药理学活性化合物
CN103126998A (zh) * 2007-09-28 2013-06-05 西梯茜生命工学股份有限公司 一种固态分散体和含有埃索美拉唑的药物组合物
DE102017008656B4 (de) 2017-09-15 2020-12-03 Glatt Maschinen- Und Apparatebau Ag Verfahren zur Regelung des Massen- oder Volumenstroms des Zerstäubergases einer Düse; Vorrichtung zur Regelung des Massen- oder Volumenstroms des Zerstäubergases einer Düse; Verwendung eines Verfahrens oder einer Vorrichtung zur Regelung des Massen- oder Volumenstroms des Zerstäubergases
JP7378393B2 (ja) * 2017-11-10 2023-11-13 オースティンピーエックス リミテッド ライアビリティ カンパニー 改善された薬物製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19710213A1 (de) * 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
WO1998050019A1 (en) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US10702509B2 (en) 2011-01-31 2020-07-07 Newmarket Pharmaceuticals Llc Animal treatments
US11166945B2 (en) 2011-01-31 2021-11-09 Newmarket Pharmaceuticals Llc Animal treatments
US11844789B2 (en) 2011-01-31 2023-12-19 Newmarket Pharmaceuticals Llc Animal treatments
US20150133504A1 (en) * 2012-05-02 2015-05-14 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
US10064849B2 (en) * 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
US10695332B2 (en) 2012-05-02 2020-06-30 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction
US10918631B2 (en) 2012-05-02 2021-02-16 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction

Also Published As

Publication number Publication date
EP1173152A2 (de) 2002-01-23
BR0012735A (pt) 2005-02-22
WO2000064414A3 (de) 2001-05-31
WO2000064414A2 (de) 2000-11-02
JP2002542275A (ja) 2002-12-10
DE19918434A1 (de) 2000-10-26

Similar Documents

Publication Publication Date Title
JP4293750B2 (ja) ベンズイミダゾール誘導体を含む経口投与製剤及びその製造方法
US5232706A (en) Oral pharmaceutical preparation containing omeprazol
FI122017B (fi) Moniyksikköinen, tabletoitu annosmuoto
KR100421347B1 (ko) 약학 혼합 제제
RU2271805C2 (ru) Препарат, содержащий натеглинид
EP1221947B1 (de) Magensaftresistente gelartige weichkapsel
US20040028737A1 (en) Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
CA2369951A1 (en) Solid pharmaceutical formulations of acid-sensitive proton-pump blockers
US8865212B2 (en) Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
JP2000514051A (ja) ベンズイミダゾール誘導体を活性成分とする経口投与用の安定な薬剤形およびその製造方法
PL190684B1 (pl) Sposób stabilizowania substancji aktywnych, którymi sa pochodne benzimidazolowe, preparat farmaceutyczny o kontrolowanym uwalnianiu tych substancji aktywnych oraz sposób wytwarzania tego preparatu
RU2259828C2 (ru) Способы стабилизации соединений на основе бензимидазола
US6582720B1 (en) Medicinal compositions adhering to stomach/duodenum
WO2009058950A2 (en) Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
AU729038B2 (en) Benzimidazole pharmaceutical composition and process of preparation
US20220031622A1 (en) Stable benzimidazole formulation
US8685448B2 (en) Pharmaceutical solid dosage form
EP1018340A9 (de) Cyclodextrin Einschlusskomplexe mit Aminosäuresalzen von Benzimidazolderivaten, deren Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen
US20070196463A1 (en) Enteric Soft Gelatin Capsule Containing Esomerpazole And Method Of Preparation
US20010053387A1 (en) Benzimidazole pharmaceutical composition and process of prepatation
US20110045068A1 (en) Pharmaceutical formulations for the oral administration of ppi
CA2544843A1 (en) Chewable tablet
US5897877A (en) Oral pharmaceutical preparation containing erythromycin base
US20040029924A1 (en) Novel pharmaceutical formulation in the form of cellulose capsules suitable for benzimidazole derivatives
EP3324946A1 (de) Pharmazeutische formulierungen aus dabigatranfreier base

Legal Events

Date Code Title Description
FZDE Dead